|
Parameter
|
Breast cancer < 50 yearsa (percentage)
|
All CBC patients (n = 247)
|
Previous RT (n = 169)
|
No RT (n = 78)
|
Carriers versus non-carriers
|
|---|
| | |
n
|
Percentage
|
n
|
Percentage
|
n
|
Percentage
|
OR for CBC after RT
|
95% CI
|
p
|
|---|
|
DDRP mutated
|
~10
|
51
|
21
|
41
|
24.3
|
10
|
12.8
|
2.18
|
1.03–4.62
|
0.043
|
|
CHEK2
|
1–2
|
15
|
6.1
|
13
|
7.7
|
2
|
2.6
|
3.17
|
0.69–14.39
| |
|
BRCA1
|
~4–5
|
27
|
11.3
|
20
|
11.8
|
7
|
9
|
1.36
|
0.55–3.37
| |
|
BRCA2
|
~0.5–1
|
5
|
2
|
4
|
2.4
|
1
|
1.3
|
1.87
|
0.21–16.98
| |
|
ATM truncating
|
~1–2
|
4
|
1.6
|
4
|
2.4
|
0
|
0
|
-
|
-
| |
| | | | | | |
1b
|
1.3
|
1.87
|
0.21–16.98
| |
- Results for all contralateral breast cancer (CBC) patients, and patients stratified by previous radiation exposure, are presented. Odds ratio (OR) and 95% confidence interval (CI) are given for mutation carriers versus non-carriers to develop radiation-associated breast cancer. DDRP, DNA-damage repair pathway; RT, radiation treatment. aPublished results; bHypothetical assumption of one case.
